Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-56286 in Healthy Participants
NCT07674940Phase 1Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of emrusolmin (6 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Time to maximum observed plasma drug concentration, Maximum observed plasma concentration and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
emrusolmin
Beyond the preview
Go deeper on NCT07674940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674940.